Cytokines in patients with lung cancer

Scandinavian Journal of Immunology

Volumn 57, Issue 2, 2003, Pages 173-178

  Matanic D ^a   Beg Zec, Z ^a   Stojanovic D ^b   Matakoric Mileusnic N ^d   Flego, V ^a   Milevoj Ribic F ^a   Dubravka, M ^c  

^a Pneumology Department   (Croatia)

^b UNIVERSITY OF RIJEKA   (Croatia)

^c KBC RIJEKA   (Croatia)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CAUSE OF DEATH; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG CANCER; LUNG CARCINOMA; LUNG LAVAGE; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; TUMOR IMMUNITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA, SQUAMOUS CELL; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN-1; INTERLEUKIN-6; LUNG NEOPLASMS; MACROPHAGES, ALVEOLAR; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037326438     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.2003.01205.x     Document Type: Article

References (43)

1. Petty LT. Lung cancer. Postgrad Med 1997;101:121-2.
2. Dentener MA, Bazil V, Von Asmuth EJ, Ceska M, Buurman WA. Involvement of CD 14 in lipopolysaccharide induced tumor necrosis factor-alpha, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J Immunol 1993;150:2885-91.
3. Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A. IL-10 inhibits cytokine production by activated macrophage. J Immunol 1991;147:3815-23.
4. Assoian RK, Fleurdelys BE, Stevenson HC et al. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc Natl Acad Sci USA 1987;84:6020-4.
5. Trepicchio LW, Wang L, Bozza M, Dorner JA. IL-11 regulates macrophage effector function through the inhibition of nuclear factor κB. J Immunol 1997;159:5661-70.
6. Koh YC, Yuan D. The effect of NK cell activation by tumor cells on antigen-specific antibody responses. J Immunol 1997;139:4745-52.
7. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998;10:573-80.
8. Abbas KA, Murphy MK, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
9. 4+ T cell subsets and cytokines involved in peripheral tolerance. Immunol Today 1997;18:533-7.
10. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997;18:263-6.
11. Emad A. Bronchoalveolar lavage: a useful method for diagnosis of some pulmonary disorders. Respir Care 1997;42:765-90.
12. Semenzato G, Spatafora M, Fertuglio C, Pace E, Dipietro V. Bronchoalveolar lavage in the immunology of lung cancer. Lung 1990;168:1041-9.
13. Rennard SI. Bronchoalveolar lavage in the diagnosis of cancer. Lung 1990;168:1035-40.
14. Landis SH, Murray TM, Bolden S, Wigo PA. Cancer statistics 1999. CA Cancer J Clin 1999;49:44-6.
15. Kennedy TC, Miller Y, Prindivile S. Screening for lung cancer revisited and the role of sputum cytology and fluorescence bronchoscopy, in a high-risk group. Chest 2000;117:72-9.
16. Van Klaveren RJ, Habbema JDF, Pedersen JH, De Konig HJ, Oudkerk M, Hoogsteden HC. Lung cancer screening by low-dose spiral computed tomography. Eur Respir J 2001;18:857-66.
17. Alexandroff AB, Robins RA, Murray A, James K. Tumor immunology: false hopes - new horizons? Immunol Today 1998;19:247-50.
18. Pisani RJ. Bronchogenic carcinoma: immunologic aspects. Mayo Clin Proc 1993;68:386-92.
19. Musiani P, Modesti A, Giovarelli M et al. Cytokines, tumor-cell death and immunogenicity a question of choice. Immunol Today 1997;18:32-6.
20. Dinarello CA. Proinflammatory cytokines. Chest 2000;118:503-8.
21. Isler P, Nicod LP. Effect of lipopolysaccharide and super antigens on T-cell activation by lung macrophages and dendritic cells. Eur Respir Rev 2000;10:133-8.
22. Nelson S. Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 2001;119:419-25.
23. Arias-Diaz J, Vara E, Torres-Melero J et al. Nitrite/nitrate and cytokine levels in bronchoalveolar lavage fluid of lung cancer patients. Cancer 1994;74:1546-51.
24. Saury A, Mauel J, Philippeaux MM, Leuenberger P. Cytostatic activity of alveolar macrophages from smokers and nonsmokers: role of interleukin-1-beta, interleukin-6 and tumor necrosis factor-alfa. Am J Respir Cell Mol Biol 1994;11:631-7.
25. Weisler CJ, Lipscome FM, Lem MW, Towes BG. Tumor killing by human alveolar macrophages and blood monocytes. Am Rev Respir Dis 1986;134:533-7.
26. Drapier JC, Wietzerbin J, Hibbs BJ Jr. Interferon-gamma and tumor necrosis factor induce the L-arginine dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 1988;18:1587-92.
27. Hibbs JR Jr, Taintor R, Vavrin Z et al. Synthesis of nitric oxide from a terminal guanidino nitrogen atom of L-arginine: a molecular mechanism regulating cellular proliferation that targets intracellular iron. In: Moncada S, Higgs EA, eds. Nitric Oxide from L-Arginine: a Bioregulatory System. Amsterdam: Elsevier, 1990, 189-223.
28. Martin JH, Edwards WS. Changes in mechanism of monocyte/macrophage mediated cytotoxicity during culture. J Immunol 1993;150:3478-85.
29. Chouaib S, Branellec D, Buurumana W. More insights into the complex physiology of TNF. Immunol Today 1991;12:141-2.
30. Larric JW, Wright SC. Cytotoxic mechanism of tumor necrosis factor-alfa. FASEB J 1990;4:3125-223.
31. Brock CS, Lee SM. Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J 2002;19:557-70.
32. Matsuyama W, Hashiguchi T, Mizoguchi A et al. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer. Chest 2000;118:948-51.
33. Farzaneh F, Trefzer U, Terry W, Walden P. Gene therapy of cancer. Immunol Today 1998;19:294-6.
34. Lucas R, Garcia I, Donari YRA et al. Both TNF receptors are required for direct TNF mediated cytotoxicity in microvascular endothelial cells. Eur J Immunol 1998;28:3577-86.
35. Dinarello CA. Role of interleukin-1 in infectious disease. Immunol Rev 1992;127:119-46.
36. Kelly J. Cytokines of the lung. Am Rev Respir Dis 1990;141: 765-88.
37. Scales EW. Structure and function of interleukin-1. In: Kunkel SL, Remic DG, eds. Cytokines in Health et Disease. New York: Marcel Dekker, 1992, 15-26.
38. Chouaib S, Asselin-Pautrel C, Marni-Chouaib F, Cainard A, Blay Y. The host tumor immune conflict: from immunosuppression to resistance and destruction. Immunol Today 1997;18:493-7.
39. Utsumi K, Takai Y, Tada T, Ohzeki S, Fujiwara H, Hamamoka T. Enhanced production of IL-6 in tumor bearing mice and determination of cells responsible for its augmented production. J Immunol 1990;145:397-403.
40. Del Prete G, Romagnani S. Human Th1 and Th2 cells functional properties, regulation of development and role in disease. In: T Cell Subsets and Cytokine Interplay in Infectious Diseases. Basel: Karger, 1996, 18-26.
41. Dett CA, Gatanga M, Ininns EK et al. Enhancement of lymphokine-activated T killer cell tumor necrosis factor receptor mRNA transcription, tumor necrosis factor receptor membrane expression, and tumor necrosis factor/lymphotoxin release by IL-1-beta, IL-4, and IL-6 in vitro. J Immunol 1991;146:1522-6.
42. Joseph SB, Miner KT, Croft M. Augmentation of naive Th1 and Th2 effector CD4 responses by IL-6, IL-1 and TNF. Eur J Immunol 1998;28:277-89.
43. Cembrzynska-Nowak M, Bienkowska M, Szkrlaz E. Exogenous interleukin-2 regulates interleukin-6 and nitric oxide but not interferon-gamma and tumor necrosis factor-alpha production in bronchoalveolar leukocytes from patients with small cell lung cancer. Arch Immunol Ther Exp 1998;46:367-74.